Agomab has reported positive data from Phase I trials of AGMB-129 and is currently conducting a Phase IIa trial with interim results expected in early 2025.
Organizations Involved
Sanofi, Invus
Company Description
Agomab Therapeutics is focused on developing treatments for fibrotic diseases, including its lead candidate AGMB-129 for fibrostenosing Crohn’s disease. The company is advancing its candidates through clinical trials with significant funding support.